Chronopin: upcoming release dates, events and other important dates

Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

On 27 October 2026 Kalshi put an official Bloomberg IPO confirmation at 3.5% before Jan 1, 2027, rising to 50% before Jan 1, 2030. The largest step in the ladder runs from Jul 1, 2028 to Jan 1, 2029 (24% to 35%), so that window is the market's most likely stretch; it is a bet on timing, not a listing date.

AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Los Angeles hosts its third Games after 1932 and 1984, using almost entirely existing venues.

Los Angeles is preparing to host the 2028 Summer Olympics with zero new venues and a 'no-car' transit plan, a bold bet for a city not known for its public transport.

ERCOT identifies Amerada Storage as 26INR0084, Amerada Solar LLC, 150.78 MW in Freestone County, targeting July 21, 2028. Screening is complete and full study started without an IA; this is a development request.

Totality passes directly over central Sydney for nearly four minutes, the first there since 1857.

Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

The five-year UPS-Teamsters agreement covering some 340,000 workers expires on 31 July 2028, and the union's president has already said a strike is coming.

EIA’s August 2026 inventory lists Steel River Solar Phase 1 (plant 70397) with a 250 MW battery and 500 MW solar, planned for August 2028. This is a phase of Cypress Creek’s broader hybrid development, rather than a proven standalone $220M/1,000 MWh battery.

MISO lists J3762 as a 430 MW solar request at Alexandria–Bison 345 kV in Clay County, Minnesota. The active Phase 2 request carries an August 1, 2028 in-service target; Great River Energy is the transmission owner, not verified developer.

AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity.

LA28’s first Paralympic Games open August 15, 2028 at SoFi Stadium in Inglewood and run through August 27. The Coliseum hosts the closing ceremony, so the opening pin is mapped to SoFi.

Boehringer Ingelheim's phase 3 trial of BI 690517 in kidney disease, chronic reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 11,000 participants. This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.

Time Out brings its market home to the city where the magazine started in 1968: 26,400 square feet over three floors at 10 Piccadilly, on a long-term partnership with The Crown Estate, as the flagship of the whole portfolio.